In FECD associated with SLC4A11 mutations, which can result in SLC4A11 misfolding and retention in the endoplasmic reticulum (ER), an AAV gene therapy approach focused on increasing the cell surface localization of SLC4A11 may be beneficial therapeutically [114]. The gene discussed is SLC4A11; the disease is Fuchs' endothelial dystrophy.